
Candel Therapeutics (CADL) Stock Forecast & Price Target
Candel Therapeutics (CADL) Analyst Ratings
Bulls say
Candel Therapeutics Inc has reported an increase in median overall survival for CAN-2409, rising from 28.8 months in the April 2024 data cut, which bolsters confidence in its efficacy and potential marketability. Furthermore, the company has enhanced its probability of FDA approval, raising expectations for CAN-2409 in prostate cancer to 45% and in pancreatic cancer to 40%, indicating strong supportive data for its mechanisms of action. The promising results from CAN-2409’s Phase 1b clinical trial, which showed a significant increase in CD8+ tumor infiltration lymphocytes, further underscore the drug's potential to translate into positive outcomes across various indications, notably in the upcoming trials for non-small cell lung cancer.
Bears say
Candel Therapeutics faces substantial risks related to the efficacy of its clinical trials for CAN-2409 and CAN-3110, which may not meet expectations compared to other treatments for the same indications. The company reported a significant net loss of $14.1 million in 4Q24, indicating ongoing financial challenges that could necessitate capital raises under unfavorable conditions, leading to potentially excessive shareholder dilution. Additionally, uncertainties surrounding regulatory requirements, unproven commercialization strategies, and the competitive landscape further compound the negative outlook for Candel's stock performance.
This aggregate rating is based on analysts' research of Candel Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Candel Therapeutics (CADL) Analyst Forecast & Price Prediction
Start investing in Candel Therapeutics (CADL)
Order type
Buy in
Order amount
Est. shares
0 shares